Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy

    • Zaloguj
    Zobacz pozycję 
    •   Strona główna Repozytorium
    • PIWet - PIB
    • Publikacje
    • Zobacz pozycję
    •   Strona główna Repozytorium
    • PIWet - PIB
    • Publikacje
    • Zobacz pozycję
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Association between gut microbiome components and immunotherapy efficacy in two small cell lung cancer cases with divergent outcomes

    Oncology in Clinical Practice

    Thumbnail
    Oglądaj/Open
    105103-490582-1-PB.pdf (430.8KB)
    Data
    2025
    Autor
    Grenda, Anna
    Iwan, Ewelina
    Krawczyk, Paweł
    Bomba, Arkadiusz
    Chmielewska, Izabela
    Bielińska, Katarzyna
    Grzywna, Aleksandra
    Szczyrek, Michał
    Jankowski, Tomasz
    Kieszko, Robert
    Galant, Natalia
    Milanowski, Janusz
    Metadane
    Pokaż pełny rekord
    Streszczenie
    Introduction. Immunotherapy can be effective in some patients with small-cell lung cancer (SCLC) with goodperformance status. However, the factors contributing to sustained treatment responses remain unclear. Theintestinal microbiome profile has emerged as a potential biomarker for the effectiveness of chemoimmunotherapyin SCLC. Evidence suggests that microbiome diversity, both in richness and abundance, may influenceimmunotherapy outcomes. The presence or absence of specific bacterial populations may also be linked totreatment success or failure. This pilot study compared the gut microbiome profile in two SCLC patients withpartial responses to chemoimmunotherapy but had distinctly different outcomes.Material and methods. Metagenomic analysis of the gut microbiome was performed using stool samplesfrom two patients collected prior to treatment initiation. Gut microbiome composition was determined basedon next-generation sequencing of the hypervariable regions of the 16S rRNA gene. Both patients receiveda treatment regimen consisting of atezolizumab, carboplatin and etoposide.Results. The progression-free survival (PFS) and overall survival (OS) were 5.7 and 10.2 months for the firstpatient and 19.9 and 34.9 months for the second patient, respectively. The patient with early progressionexhibited reduced species-level diversity compared to the long-term responder. Additionally, bacteria fromthe families Lachnospiraceae, Akkermansiaceae were found to be more prevalent in the patient with greaterimmunotherapy benefit. Conversely, the families Enterobacteriaceae, Succinivibrionaceae, Streptococcaceae,and Desulfovibrionaceae were more abundant in the patient with short survival than in patients with prolongedresponse.Conclusions. Bacteria residing in the gut may affect the efficacy of chemoimmunotherapy in SCLC patientsand represents a promising candidate for predictive biomarkers of treatment response and efficacy
    URI
    https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/105103
    Zbiory
    • Publikacje [672]

    DSpace software copyright © 2002-2016  DuraSpace
    Kontakt z nami | Wyślij uwagi
    Theme by 
    Atmire NV
     

     

    Przeglądaj

    Całe RepozytoriumZbiory i kolekcjeDaty wydaniaAutorzyTytułyTematyTa kolekcjaDaty wydaniaAutorzyTytułyTematy

    Moje konto

    Zaloguj

    Statystyki

    Przejrzyj statystyki użycia

    DSpace software copyright © 2002-2016  DuraSpace
    Kontakt z nami | Wyślij uwagi
    Theme by 
    Atmire NV